Cholangiocarcinoma (CCA) is a biliary epithelial tumour that can emerge at any point in the biliary tree. It is commonly classified based on its anatomical site of development into intrahepatic cholangiocarcinoma (ICC), perihilar cholangiocarcinoma (PCC) and distal cholangiocarcinoma (DCC), each of which is associated with varying patient demographics, molecular characteristics and treatment options. CCA patients have poor overall prognoses and 5-year survival rates. Additionally, CCA is often diagnosed at an advanced stage, with surgical treatment restricted to early-stage disease. Owing to an increase in the incidence of ICC, that of CCA is also on the rise, with a corresponding increase in the associated mortality, particularly in South America and Asia. Therefore, the development of an effective treatment is crucial to improve the survival of CCA patients. We aimed to systematically review the current understanding of advanced CCA treatment and discuss potential effective strategies.
CITATION STYLE
Wang, M., Chen, Z., Guo, P., Wang, Y., & Chen, G. (2021, January 1). Therapy for advanced cholangiocarcinoma: Current knowledge and future potential. Journal of Cellular and Molecular Medicine. Blackwell Publishing Inc. https://doi.org/10.1111/jcmm.16151
Mendeley helps you to discover research relevant for your work.